Myriad Rebounds After CMS Reversal on BRACAnalysis Pricing

Shares of Myriad Genetics (Salt Lake City) have continued to rise following last week’s announcement by the Centers for Medicare and Medicaid Services (CMS) that it had reversed its previous cut in payment for the company’s BRACAnalysis test (CPT 81211), increasing the reimbursement rate to $2,184. The new rate is an increase of 52 percent…